Literature DB >> 2899235

Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants.

G H Cassell1, K B Waites, D T Crouse, P T Rudd, K C Canupp, S Stagno, G R Cutter.   

Abstract

Endotracheal aspirates from 200 infants who weighted less than or equal to 2500 g and who had evidence of respiratory disease were cultured within 24 h of birth for mycoplasmas, chlamydiae, viruses, and bacteria to evaluate the relation between lower respiratory tract infection and development of chronic lung disease and/or death. Ureaplasma urealyticum, an organism not visible on gram stain, not recovered on routine bacteriological media, and not susceptible to antibiotics commonly used to treat neonatal infections, was the single most common organism isolated. 14% of isolates were from infants born by caesarean section with intact membranes, which indicated that infection had occurred in utero. The findings probably represented true infection of the lower respiratory tract because the organism was recovered in pure culture in numbers greater than 10(3) from 85% of the infants, and also from the blood in 26% of infants. Those infants less than or equal to 1000 g with Ureaplasma urealyticum infection of the lower respiratory tract were twice more likely to have chronic lung disease or to die than were infants of similar birth-weight but who were uninfected, or infants greater than 1000 g. Very-low-birth-weight infants infected with ureaplasmas did not differ from those uninfected, either in demographic features or in potential risk factors for chronic lung disease.

Entities:  

Mesh:

Year:  1988        PMID: 2899235     DOI: 10.1016/s0140-6736(88)92536-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  63 in total

1.  Differentiation of two biovars of Ureaplasma urealyticum based on the 16S-23S rRNA intergenic spacer region.

Authors:  R Harasawa; Y Kanamoto
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Factors affecting the incidence of chronic lung disease of prematurity in 1987, 1992, and 1997.

Authors:  B N Manktelow; E S Draper; S Annamalai; D Field
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

Review 3.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 4.  Paediatric infectious diseases: some recent advances and future priorities.

Authors:  P A Davies
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

5.  Comparison of the Mycoplasma Duo test with PCR for detection of ureaplasma species in endotracheal aspirates from premature infants.

Authors:  Fook-Choe Cheah; Trevor P Anderson; Brian A Darlow; David R Murdoch
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Serotype diversity and antigen variation among invasive isolates of Ureaplasma urealyticum from neonates.

Authors:  X Zheng; H L Watson; K B Waites; G H Cassell
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

7.  Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth.

Authors:  P Groneck; B Goetze-Speer; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

8.  Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia.

Authors:  K Tullus; G W Noack; L G Burman; R Nilsson; B Wretlind; A Brauner
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

9.  Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas.

Authors:  Kathleen A Stellrecht; Amy M Woron; Nada G Mishrik; Richard A Venezia
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.